Long-term persistence of humoral and cellular immune responses induced by an AS03_A-adjuvanted H1N1 2009 influenza vaccine

References

• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740 - 5; http://dx.doi.org/10.1016/j.vaccine.2009.12.014; PMID: 20034605
   PubMed Web of Science ®Google Scholar
• Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837 - 44; http://dx.doi.org/10.1016/j.vaccine.2010.06.065; PMID: 20600478
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, et al. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888 - 93; http://dx.doi.org/10.4161/hv.6.11.12851; PMID: 20980795
   PubMed Web of Science ®Google Scholar
• Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835 - 43; http://dx.doi.org/10.1128/CVI.00480-10; PMID: 21450978
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668 - 77; http://dx.doi.org/10.1086/655830; PMID: 20687838
   PubMed Web of Science ®Google Scholar
• Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733 - 44; http://dx.doi.org/10.1093/infdis/jir641; PMID: 22315336
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91 - 101; http://dx.doi.org/10.1016/S1473-3099(10)70296-6; PMID: 21168369
   PubMed Web of Science ®Google Scholar
• Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266 - 73; http://dx.doi.org/10.1016/j.vaccine.2010.10.038; PMID: 21034828
   PubMed Web of Science ®Google Scholar
• Saitoh A, Tamura S, Nagai A, Tsuchida N, Sako M, Maekawa T, et al. Clinical evaluation of an AS03-adjuvanted pandemic influenza H1N1 2009 vaccine in children (Preliminary report). [Japanese.] J Jap Pediatr Soc. 2011; 115:578 - 84
   Google Scholar
• Saitoh A, Nagai A, Tenjinbaru K, Li P, Vaughn DW, Roman F, et al. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Hum Vaccin Immunother 2012; 8:749 - 58; http://dx.doi.org/10.4161/hv.19684; PMID: 22495117
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849 - 57; http://dx.doi.org/10.1016/j.vaccine.2009.10.017; PMID: 19835828
   PubMed Web of Science ®Google Scholar
• Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383 - 91; http://dx.doi.org/10.1016/j.vaccine.2008.08.046; PMID: 18801398
   PubMed Web of Science ®Google Scholar
• Cowling BJ, Ng S, Ma ES, Cheng CK, Wai W, Fang VJ, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010; 51:1370 - 9; http://dx.doi.org/10.1086/657311; PMID: 21067351
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Early Results: NIAID Trial Supports Co-Administration of 2009 H1N1 Influenza Vaccine and Seasonal Influenza Vaccine Bulletin 2009; October 09, 2009. Available: http://www.niaid.nih.gov/news/newsreleases/2009/pages/h1n1plusseasonalvax.aspx. Accessed: February 20, 2012.
   Google Scholar
• Regner S, Peeters M, Schmitt B, Vaman T, Devaster JM, Rombo L. Immunogenicity, safety and reactogenicity of the AS03A-adjuvanted influenza A (H1N1) 2009 vaccine following sequential or co-administration with a licensed seasonal trivalent vaccine in adults aged ≥61 years. Accepted to be presented at the XIII International Symposium on Respiratory Viral Infections 2011, 13−16 March 2011, Rome, Italy.
   Google Scholar
• Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375:49 - 55; http://dx.doi.org/10.1016/S0140-6736(09)62039-0; PMID: 20018367
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012; 8:1119 - 25; http://dx.doi.org/10.4161/hv.21081; PMID: 22854661
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, et al. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother 2012; 8:260 - 6; http://dx.doi.org/10.4161/hv.18469; PMID: 22426369
   PubMed Web of Science ®Google Scholar
• Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008; 7:467 - 79; http://dx.doi.org/10.1586/14760584.7.4.467; PMID: 18444893
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (GSK) Biologicals. Pandemrix™ suspension and emulsion for emulsion for injection. Summary of product characteristics. March 02, 2010.
   Google Scholar
• Hehme NW, Künzel W, Petschke F, Gisela T, Carmen R, Christian Van H, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig 2002; 22:751 - 69; http://dx.doi.org/10.2165/00044011-200222110-00004
   Web of Science ®Google Scholar
• European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
   Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580 - 9; http://dx.doi.org/10.1016/S0140-6736(07)61297-5; PMID: 17707753
   PubMed Web of Science ®Google Scholar
• Yang H, Carney P, Stevens J. Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin. PLoS Curr 2010; 2:RRN1152; http://dx.doi.org/10.1371/currents.RRN1152; PMID: 20352039
   PubMedGoogle Scholar
• Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443 - 54; http://dx.doi.org/10.1007/s10875-010-9490-6; PMID: 21174144
   PubMed Web of Science ®Google Scholar